NEW YORK (GenomeWeb News) — Nanogen's plan to buy diagnostics firm Elitech is unlikely to happen as certain closing conditions for the deal probably won't be met by March 31, 2009, Nanogen said today.

San Diego-based Nanogen said the companies have agreed to allow Nanogen the right to consider alternatives to the reverse acquisition, which was valued at €66.5 million ($98.5 million) when the companies forged the plan in August 2008.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Sponsored by

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Sponsored by

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.